Towards net zero: asthma care

What you need to knowHydrofluorocarbon propellants used in pressurised metered dose inhalers (pMDIs) disproportionately contribute to healthcare’s environmental impactReduced use of pMDIs improves planetary outcomes as well as clinical outcomes for patientsWhenever clinically appropriate, consider low carbon inhalers (dry powder or soft mist) rather than high carbon pMDIsSeek opportunities to review asthma care at every consultationAsthma affects over 260 million people and causes more than 460 000 premature deaths annually worldwide.1 There is variation in asthma care and its carbon footprint globally: the UK, for example, has a high hospital admission rate and mortality for asthma compared with other high income countries,12 and it has a high carbon footprint from inhalers. At the centre of these two problems is an over-reliance on pressurised metered dose inhalers (pMDIs)—short acting β agonist (SABA) reliever pMDIs in particular3 but also inhaled corticosteroid preventer pMDIs.45 There is no clinical rationale for this inter-country variation,…
Read Original Article: Towards net zero: asthma care »